D-index: A New Scoring System in Febrile Neutropenic Patients for Predicting Invasive Fungal Infections

Objective: Neutropenia is a critical risk factor for invasive fungal infections (IFIs). We retrospectively performed this study to assess the performance of the D-index, a new test that combines both the duration and the severity of neutropenia, in predicting IFIs among patients with acute myelogenous leukemia.

Materials and Methods: Fifteen patients with IFIs and 28 patients who did not develop IFIs were enrolled in the study. The D-index was defined as the area over the neutrophil curve, whereas the cumulative-D-index (c-D-index) was the area over the neutrophil curve from the start of neutropenia until the first clinical manifestation of IFI.

Results: The D-index and the c-D-index tended to be significantly higher in patients with IFIs, with medians of 10,150 (range: 4000-22,000) and 5300 (range: 2300-22,200), respectively (p=0.037 and p=0.003, respectively). The receiver operating characteristic analyses showed that there was a cutoff point of 3875 for the D-index in predicting IFI; the sensitivity, specificity, and positive and negative predictive values were 100%, 67.9%, 35.4%, and 100%, respectively. There was also a cutoff point of 4225 for the c-D-index in predicting IFI; the sensitivity, specificity, and positive and negative predictive values for the c-D-index were 93.3%, 71.4%, 36.6%, and 98.4%.

Conclusion: The D-index and especially the c-D-index could be useful tools with high negative predictive value to exclude as well as to predict IFIs in the management of neutropenic patients.

Keywords: Neutropenia, D-index, Cumulative-D-index, Hematological malignancies, Invasive fungal infections

Introduction

Invasive fungal infections (IFIs) are major life-threatening infections among immunocompromised patients with hematologic malignancies. Although there has been significant progress in the management of febrile neutropenic cancer patients related to increasing protective measures and antifungal agents, neutropenia is still a critical risk factor for IFI. Profound (<100 neutrophils/µL) and prolonged (>10 days) neutropenia is associated with a higher risk of invasive aspergillosis [1,2,3,4,5,6,7].
Several scoring systems have been developed to categorize febrile neutropenic patients into risk groups. These systems usually take neutropenia duration into account. Recently, Portugal et al. developed indexes called the D-index and the cumulative-D-index (c-D-index), which take into account both the duration and the intensity of neutropenia to predict the IFI risk [8]. We performed this study to assess the performance of these new tests in predicting IFIs among patients with acute myelogenous leukemia (AML).

Materials and Methods

Patients

The Department of Adult Hematology of Ankara University's Faculty of Medicine, a 56-bed institution, is one of the main regional centers of hematology and bone marrow transplantation in Ankara. Patients with newly diagnosed AML receiving first induction or with relapsed or refractory AML, and who developed neutropenia at this center between March 2011 and March 2012, were included in the study. Among these patients, 15 patients with IFIs and 28 patients who did not develop IFIs were enrolled. We selected controls with the same underlying disease and leukemia status. IFIs were classified as possible, probable, or proven according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) revised criteria [9]. Only the proven and probable cases were included in the study (proven: 2, probable: 13). Clinical and epidemiological data were collected by structured survey forms during daily infectious disease consultation visits. The patients who developed IFIs were compared with controls regarding age, sex, underlying disease, comorbidities, type of chemotherapy, antibacterial and antifungal prophylaxis, mortality rate, duration of neutropenia, profound neutropenia, D-index, and c-D-index. The study was approved by the local ethics committee.

D-index and Cumulative-D-index Calculation

The absolute neutrophil count was recorded in patients and controls. The D-index is an index based on a graph showing the absolute neutrophil counts over the course of the episode of neutropenia (Figure 1). It is geometrically the area over the neutrophil curve. The D-index was calculated as the difference between the observed area under curve (AUC) (Ao) and the expected neutrophil area (Ae) if the patient did not develop neutropenia (D-index: Ae-Ao). Ae was calculated by the trapezoidal method, while Ae is the product of 500 and the number of days with neutropenia (Ae: 500/µL x days with neutropenia). An XLA add-in, developed by Usansky et al., was used to apply the trapezoidal method [10]. We also calculated the c-D-index, which is from the start of neutropenia until the date of first clinical manifestation of IFI in patients. The date of first clinical manifestation was defined by 3 specialists (2 from the department of infectious diseases and one from the department of hematology), and then their results were compared with each other. The clinical manifestations were cough, nasal discharge, pleuritic chest pain, hemoptysis, skin nodules, and stomachache with elevated liver enzymes.

Power Analysis

The D-index was considered as the primary outcome variable for this study. Group sample sizes of 25 and 15 achieved 82% power to detect a difference of 5000 between the null hypothesis that both group means were 4000 and the alternative hypothesis that the mean of group 2 was 9000 with estimated group standard deviations of 5000 and 5000 and with a significance level (alpha) of 0.05 using a 2-sided Mann-Whitney U test, assuming that the actual distribution was normal.

Statistical Analysis

Mean ± standard deviation, median (minimum-maximum), or percentage values are given as descriptive statistics as applicable. Dichotomous variables were compared using the chi-square or Fisher's exact test. Test of normality was assessed by Shapiro-Wilk test. Comparison of continuous variables between fungal and control groups was analyzed by Mann-Whitney U test. A receiver operating characteristic (ROC) curve analysis was performed to evaluate the ability of the D-index and c-D-index to predict IFI. Positive and negative predictive values were calculated by using cutoff values obtained from ROC analysis. A multiple logistic regression was performed to identify the independent risk factors of outcome variable and the adjusted odds ratio (OR) was calculated. SPSS 15.0 for Windows was used for statistical analysis. A p-value of less than 0.05 was considered significant.

Results

A total of 15 patients with IFIs and 28 controls were enrolled during the 1-year study. The clinical and epidemiological data of the patients are shown in Table 1. Those that developed IFIs were older than the controls. The lung was the most common site of fungal infection (86.7%). There were no significant differences between patients and controls regarding sex, status of underlying disease, chemotherapies, and comorbidities. All patients were given fluconazole prophylaxis. The duration and the severity of neutropenia were significantly higher in IFI patients. Consequently, the D-index and the c-D-index tended to be significantly higher in patients with IFIs, with a median of 10,150 (range: 4000–22,000) and 5300 (range: 2300–22,200), respectively.
The ROC analyses showed that both the D-index and the c-D-index could be used to predict IFIs [AUC ± standard error (SE): 0.914±0.042, p<0.001 and AUC ± SE: 0.779±0.074, p=0.003, respectively; Figures 2 and 3]. There was a cutoff point of 3875 for the D-index in predicting IFIs; the sensitivity, specificity, and positive and negative predictive values were 100%, 67.9%, 35.4%, and 100%, respectively. There was also a cutoff point of 4225 for the c-D-index in predicting IFI; the sensitivity, specificity, and positive and negative predictive values for the c-D-index were 93.3%, 71.4%, 36.6%, and 98.4%.

Discussion

Fungal infections are responsible for most of the deaths from infections in febrile neutropenic patients with hematological malignancies, with mortality rates of 50%-80%. Although the initiation of appropriate antifungal therapy is crucial and associated with improved outcomes, the management of antifungal treatment in this heterogeneous population is a matter of great research [3,6,11,12,13,14].

Empirical antifungal therapy, which is the administration of systemic antifungals for persistent and recurrent fever 96 h after broad-spectrum antibacterial treatment, has been the standard of care for many years. Since the fever-based approach increased antifungal usage, preemptive or diagnostic-driven antifungal therapy, which is usually guided by clinical or radiological signs and serum biomarkers (galactomannan, 1,3-beta-D-glucan, Yılmaz G, et al: D-index
polymerase chain reaction), was defined [15]. Studies comparing these 2 approaches reported that the rate of antifungal usage was reduced and no increase in mortality was observed with diagnostic-driven antifungal therapy. However, the success of this strategy depends on the availability and the performance of the tests predicting IFI [15,16,17,18].

IFIs are difficult to predict and diagnose. Host factors are important for predicting IFIs as well, as they are the determinants of the outcome [6]. Neutropenia, one of the host factors, is still a significant risk factor, and resolution of neutropenia has a key role in complete recovery from an IFI [6,19]. The duration and also the severity of neutropenia are critical, but there was no practical tool that combined both the duration and the severity of neutropenia in its evaluation approach.

Recently, Portugal et al. developed the D-index and c-D-index, simple indexes to calculate, which combine both the duration and the intensity of neutropenia [8]. They reported that these indexes were superior to the duration of neutropenia for predicting IFI. Shortly afterwards, Kimura et al. also showed that early pulmonary infections in hematopoietic stem cell transplantation recipients tended to occur in patients with higher D-index and c-D-index scores [20]. In accordance with these results, higher D-index and c-D-index scores were associated with IFIs in our study. We presume that the c-D-index score in particular, available earlier than the D-index score, has the ability to discriminate among patients with the same duration but different severities of neutropenia according to IFI development.

Previous studies documented increased risks for fungal infections in older patients [11,21,22]. In this study, univariate analysis showed that the median age was higher for patients with IFIs than the controls, at 52.5±15.1 and 42.5±14.6 years, respectively. However, the D-index and c-D-index still tended to be significantly higher for the IFI group than the controls when age and sex were adjusted [OR: 1.54, 95% confidence interval (CI): 1.28-2.19].

Although 20% of the stem cell transplantation centers in Turkey use diagnostic-driven approaches, empirical treatment is still the main approach [23]. This means that a significant proportion of patients are receiving antifungal therapy unnecessarily and we need helpful tools to assess the risk of IFI besides chest computed tomography scan and the use of serum biomarkers. The galactomannan test is the only available serum biomarker at our center. It is performed twice weekly but the results are reported with a 1-week delay. Hence, the c-D-index could be integrated with other parameters to promote diagnostic-driven therapy in such centers.

The negative predictive values of the D-index and c-D-index for IFI prevalence of 15% was 100% (95% CI: 89.8-102.0) and 98.4% (95% CI: 87.2-101.6) using the cutoff values of 3875 and 4225, respectively. The high negative predictive values suggest that this new tool should work to exclude invasive fungal infections. Serum biomarkers such as galactomannan and beta-glucan for fungal infections have some false positives. Thus, when interpreting the results in these situations, a c-D-index of less than 4225 supports the false positivity of other biomarkers and suggests that antifungal therapy could be delayed.

This study has some limitations. The first is the small number of patients. Since April 2012, AML patients with induction therapy have started to receive antifungal prophylaxis (posaconazole) regularly at our center and the impact of this prophylaxis could not be assessed in this study. The second limitation is the underlying disease, due to the fact that only patients with AML were evaluated. Thus, we could not investigate the applicability of this new test with other malignancies.

**Conclusion**

In conclusion, this study confirms that the D-index, and in particular the c-D-index, could be useful tools to exclude as well as to predict IFIs. These cheap and simple tests stand out with high negative predictive values in daily management of neutropenic patients.

**Ethics**

Ethics Committee Approval: The study was approved by the local ethics committee, Informed Consent: N/A.

**Authorship Contributions**

Medical Practices: Belgin Coşkun; Concept: Gülden Yılmaz, Design: Alpay Azap, Hamdi Akan; Data Collection or Processing: Belgin Coşkun, Gülden Yılmaz, Atilla Elhan; Analysis or
Interpretation: Gülden Yılmaz, Belgin Coşkun, Atilla Elhan, Alpay Azap, Hamdi Akan; Literature Search: Gülden Yılmaz, Belgin Coşkun, Atilla Elhan, Alpay Azap, Hamdi Akan; Writing: Gülden Yılmaz, Belgin Coşkun, Atilla Elhan, Alpay Azap, Hamdi Akan.

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

1. Kriengkauykiat J, Ito J, Dadwai S. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol 2011;3:175-191.

2. Michallet M, Ito J. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 2009;27:3398-3409.

3. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, Oliveira JS, Paraguay N, Duboc G, Voltareli JC, Maiolino A, Pasquini R, Souza CA. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003;98:315-319.

4. De Pauw BE, Meunier F. The challenge of invasive fungal infection. Clin Epidemiol 2011;3:175-191.

5. Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, Chevrier S, Meunier C, Lebet C, Aupée M, Caulet-Maugendre S, Faucheux M, Leborgon L, Leray E, Guiguern C, Gangneux JP. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006;43:577-584.

6. Nucci M. Use of antifungal drugs in hematology. Rev Bras Hematol Hemoter 2012;34:383-391.

7. Offidani M, Covatta L, Olivieri A, Rupoli S, Frayfer J, Mele A, Manso E, Montanari M, Centurioni R, Leoni P. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 1999;24:1079-1087.

8. Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area under the neutrophil curve. J Clin Oncol 2009;27:3849-3854.

9. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Loeffler J, Ruhnke M; IDEA study investigators. Immediate versus deferred empirical antifungal therapy in neutropenic patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. J Clin Microbiol Infect Dis 2013;32:679-689.

10. Usansky JI, Desai A, Tang-Liu D. PK Functions for Microsoft Excel. Irvine, CA, USA, Department of Pharmacokinetics and Drug Metabolism of Allergan Inc. (available at www.boomer.org/pkin/xcel/pkf/pkf.doc).

11. Marr KA, Carter RA, Bodeck M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-4366.

12. Li L, Wang J, Zhang W, Yang J, Chen L, Lv S. Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: a single center study of 190 recipients. Scand J Infect Dis 2012;44:100-107.

13. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917.

14. Upton A, Kirby KA, Carpenter P, Bodeck M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-540.

15. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Logrou K, Verbeeken E, Wilmer A, Verhagen J, Boogaerts M, Van Eldere J, Galactomannan and computed tomography based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-1250.

16. Corduene C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhédin N, Isnard F, Aucouturier A, Kohnowski F, Foulet F, Kuentz M, Maisson P, Bretagne S, Schwarzinger M. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-1051.

17. Hebart H, Klingebiel T, Loeffler J, Tollemar J, Ljungman P, Wandt H, Schaefer-Eckart K, Bornsbusch HJ, Meisner C, Engel C, Stenger N, Mayer T, Ringden O, Eisele H. A prospective randomized controlled trial comparing PCR based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009;43:553-561.

18. Maschmeyer G, Heinz WJ, Hertenstein B, Horst HA, Requadt C, Wagner T, Cornely OA, Löffler J, Ruhnke M; IDEA study investigators. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. Eur J Clin Microbiol Infect Dis 2013;32:679-689.

19. Cesaro S, Pagano L, Caira M, Carraro F, Luciani M, Russo D, Colombani A, Morello W, Viale P, Rossi G, Tridelio G, Pegoraro A, Nosari A, Aversa F; Hemato-Chart Group. A prospective, multicenter survey on antifungal therapy in neutropenic pediatric haematology patients. Mycoses 2013;56:51-57.

20. Kimura S, Oshima K, Sato K, Sato M, Terasako K, Hideki N, Kikuchi M, Okuda T, Cornely OA, Löffler J, Ruhnke M; IDEA study investigators. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients undergoing bone marrow transplantation. Bone Marrow Transplant 2010;45:987-995.

21. Wald A, Liem H, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-1466.

22. Baddley J, Strawb T, Salzman D, Pappas P. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319-1324.

23. Akan H. Antifungal treatment in stem cell transplantation centers in Turkey. In: 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27-30 April 2013.